Natural Capsules
165.97
+2.28(+1.39%)
Market Cap₹171.63 Cr
PE Ratio-13.85
IndustryHealthcare
Company Performance:
1D+1.39%
1M-9.22%
6M-22.18%
1Y-33.49%
5Y-33.49%
View Company Insightsright
More news about Natural Capsules
13Nov 25
Natural Capsules Limited Reports Mixed Q2 Results, Declines Subsidiary Rights Issue
Natural Capsules Limited announced Q2 and H1 FY2025-26 results. Standalone performance showed resilience with Q2 revenue at Rs. 4,458.02 lakhs and net profit at Rs. 281.05 lakhs. H1 standalone revenue reached Rs. 8,882.31 lakhs with Rs. 533.35 lakhs net profit. Consolidated results revealed challenges with Q2 net loss of Rs. 677.85 lakhs and H1 net loss of Rs. 1,286.95 lakhs, mainly due to subsidiary Natural Biogenex's performance. The company decided against subscribing to Natural Biogenex's rights issue, citing ongoing project commitments. Segment-wise, Capsules generated Rs. 4,458.02 lakhs revenue with Rs. 514.96 lakhs profit, while API segment showed Rs. 122.24 lakhs revenue but higher profitability at Rs. 859.45 lakhs.
 no imag found
30Sept 25
Natural Capsules Subsidiary Cancels Rights Issue Due to Non-Subscription
Natural Capsules Limited announced that its material subsidiary Natural Biogenex Private Limited has decided not to proceed with the allotment of shares under the previously approved rights issue worth ₹1.11 crore due to non-subscription by the major shareholder. The company also disclosed the upcoming retirement of Chief Operating Officer Mr. MVN Kutty due to superannuation, effective September 30, 2025.
 no imag found
05Aug 25
Natural Capsules Limited Shareholders Approve Key Board Changes and Appointments at 32nd AGM
Natural Capsules' 32nd AGM saw shareholders approve several important resolutions. Mr. Tekkar Yashwanth Prabhu will continue as Non-Executive Independent Director beyond 75 years. Mr. Sathyanarayana Mundra was reappointed as Whole Time Director for three years. Mr. R. Parthasarathy was appointed as Secretarial Auditor for five years. Other approvals included adoption of financial statements, reappointment of Mr. Sushil Kumar Mundra, related party transactions, and commission for Non-Executive Directors. All resolutions passed with overwhelming majority.
 no imag found
04Aug 25
Natural Capsules Reports Mixed Q1 Results: Standalone Profit Amid Consolidated Loss
Natural Capsules reported mixed Q1 financial results. Standalone performance showed growth with Rs 44.24 crore revenue and Rs 2.52 crore net profit. Consolidated results reflected challenges, with Rs 45.20 crore revenue but Rs 5.58 crore net loss. The Capsules segment remained profitable, while the new API segment incurred significant losses. The subsidiary, Natural Biogenex Private Limited, started operations recently and is yet to reach full revenue potential.
 no imag found
Natural Capsules
165.97
+2.28
(+1.39%)
1 Year Returns:-33.49%
Industry Peers
Sun Pharmaceutical
1,697.50
(-1.01%)
Divis Laboratories
6,168.50
(-0.27%)
Torrent Pharmaceuticals
4,078.00
(+0.02%)
Cipla
1,331.50
(+0.11%)
Dr Reddys Laboratories
1,268.10
(-0.53%)
Lupin
2,199.30
(-0.53%)
Zydus Life Science
904.70
(-1.76%)
Mankind Pharma
2,060.50
(-0.89%)
Aurobindo Pharma
1,145.60
(-1.06%)
Alkem Laboratories
5,402.50
(-7.97%)